

XVIII ASSEMBLEA MANGO

Ricerca Clinica e Traslazionale in Ginecologia Oncologica

MILANO, 2-3 LUGLIO 2021

Approximation of the state of t





SOCIETA' ITALIANA DI CANCEROLOGIA

Con il Patrocinio di:






Antiangiogenetici e Parp inibitori in prima linea: quale algoritmo nel 2021? A. Gadducci, Pisa

Consolidation and maintenance therapy for advanced EOC pts in complete response after first-line CT

- ✓ Whole abdomen radiotherapy
- ✓ Intraperitoneal chromic phosphate (32P)
- ✓ Radioimmunotherapy
- ✓ Intraperitoneal chemotherapy
- \checkmark High-dose chemotherapy with hematopoietic support
- \checkmark Prolonged administration of 1-line chemotherapy
- Concomitant or sequential addition of a third cytotoxic agent to CBDCA/PTX




ANTI-VEGF TARGETING: BEVACIZUMAB in FRONT-LINE



Bevacizumab

HR: 0.73 10.4 vs 13.9 mos Median D: 3.5 mos





Burger et al. N Engl J Med 2011



Median D: 2.4 mos




XVIII ASSEMBLEA MANGO MILANO, 2-3 LUGLIO 2021

WNSGO-CTL

Rigshospitalet

GOG 218 TRIAL





Standard CT <u>+</u> BEV for pts with newly diagnosed EOC (ICON7): OS results of a phase 3 randomised trial

	All	pts	High-risk pts*		
	СТ	CT + BEV	СТ	CT+ BEV	
OS (95% <i>C</i> I)	58,6	58,0	30,2	39,7	
(months)	53,5-67,5	52,4-66,9	27,0-34,3	36,0-44,2	
P value		0,85		0,03	

*stage IV, inoperable stage III, or suboptimally debulked (>1 cm) stage III

Oza et al, Lancet Oncol. 2015



Exploratory outcome analyses according to stage and/or RD in the ICON7 trial for newly diagnosed EOC

PFS (months)

	Stage III-b-IV (no RD) (n. 411)	Stage III-b-IV (RD) (n.749)
CT + BEV	29,5	16,7
СТ	24,3	12,0
HR (95%CI)	0.77 (0.59.0.99)	0.81 (0.69-0.95)

Gonzalez Martinet et al. 2019



Incorporation of BEV in first-line therapy of EOC : Real World observational studies

- NCT01697488: Non-interventional Surveillance Study on First-line BEV in Combination With CBDCA/PTX in Patients With Advanced Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (OTILIA)
- NCT01863693: Observational Study of BEV in Combination With Chemotherapy as First-Line Treatment in Patients With Advanced Ovarian Cancer (OSCAR1)
- JGOG3022: BEV Combined with platinum-taxane chemotherapy as firstline treatment for advanced ovarian cancer: a prospective observational study of safety and efficacy in Japanese patients (Komiyama et al.)
- ROBOT TRIAL: Real-World Study of Adding BEV to Chemotherapy for Ovarian, Tubal, and Peritoneal Cancer as Front-Line or Relapse Therapy



BEV combined with platinum-taxane CT as 1st-line treatment for advanced EOC: a prospective observational study of safety and efficacy in Japanese patients (JGOG3022 trial)

346 (293 evaluable) pts prospectively enrolled stage III -IV EOC to receive PTX + CBDCA q3w Cycles 1-6 + BEV q3w Cycles 2-22-> median PFS= 16.3 months

	n	Re	sponse rate (in p	ots with measurable RD)
		%	95% <i>C</i> I	
All cases	89	77.5	67.4-85.7	
Serous	60	81.7	69.6-90.5	
Endom	10	80	44.4-97.5	
Clear cell	11	63.6	30.8-89.1	
Others	8	62.5	24.5-91.5	
Response rate to	PTX/CBDCA:	46.7%	in ovarian CCC	(Sugiyama 2016)



Ricerca Clinica e Traslazionale in Ginecologia Oncologica

Komiyama et al 2019

Incorporation of BEV in first-line therapy of EOC : Real World observational studies

Global Study to Assess the Addition of BEV to CBDCA + PTX NCT01239732 ROSIA as Front-line Treatment of Epithelial Ovarian Cancer, Fallopian Tube Carcinoma or Primary Peritoneal carcinoma NCT01706120: Study of Clinical and Biological Prognostic Factors in Patients MITO16/MANGO-2 With Ovarian Cancer Receiving CBDCA +PTX With BEV to Evaluate NCT01462890: A Prospective Randomised Phase III Trial BOOST **Optimal Treatment Duration of First-line BEV in Combination** With CBDCA + PTX in Patients With Primary Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer



Efficacy and safety of BEV -containing therapy in newly diagnosed EOC : ROSiA Single-Arm Phase 3B Study

- ✓ 1021 pts with G3 stage I-IIA or IIB-IV EOC (Eligibility criteria similar to ICON 7)
- ✓ BEV [15 mg/kg (89%) or 7.5 mg/kg q3w] + PTX [175 mg/m² q3w or 80 mg/m² weekly] + CBDCA [AUC5-6 q3w for 4-8 cycles], followed by BEV maintenance for up to 24 months
- ✓ BEV for > 1 year: 62%, > 15 months: 53%, and > 2 years: 29%
- \checkmark Median PFS: 25.5 months (in the whole series)
 - 18.3 months in high-risk patients
 - 32.0 months in non high-risk patients

Oza et al 2017



Efficacy and safety of BEV -containing therapy in newly diagnosed EOC : ROSiA Single-Arm Phase 3B Study




FIGURE 2

Cumulative number of patients developing hypertension or proteinuria over time.



Ricerca Clinica e Traslazionale in Ginecologia Oncologica

BEV + CBDCA+ PTX in the 1st line treatment of advanced EOC patients: the phase IV MITO-16A/MaNGO-OV2A study

- ✓ 398 pts :CBDCA (AUC 5) PTX (175 mg/m²) + BEV (15 mg/kg) q3w x 6 cycles followed by BEV until cycle 22nd (Median follow-up: 32.3 months)
- ✓ Median PFS: 20.8 months, median OS: 41.1 months. Efficacy and toxicity profile comparable to previous data.
- \checkmark Prognostic variables PS, stage, and RD after primary surgery.
- ✓ Neither baseline PA nor the development of hypertension during BEV were prognostic factors.

Daniele et al 2021



Optimal treatment duration of BEV combined with CBDCA/PTX in pts with primary EOC: a multicenter open-label randomized 2-arm phase 3 ENGOT/GCIG trial of the AGO Study Group, GINECO, and NSGO (BOOST)

✓ 927 stage IIB-IV EOC pts treated with PDS and PTX (175 mg/m²) + CBDCA AUC
 5 + BEV 15 mg/kg q3w

RANDOM

	BEV \times 15 months	BEV \times 30 months	HR (95% CI)
median PFS (months)	24.2	26.0	0.99 (0.85-1.15)
median OS (months)	54.3	60.0	1.04 (0.87-1.23)




Pfisterer et al 2021

Efficacy according to BRCA and genomic instability


	PRIMA	SOLO1	VELIA	PAOLA 1
ITT	HR 0.62 0.5-0,76	HR 0,30 0.23-0,41	HR 0,68 0,56-0,83	HR 0.59 0,49-0,72
HRD	HR 0.43 0.31-0,59		HR 0.57 0.43-0,76	HR 0.33 0.25-0,45
HRD+BRCAm	HR 0.40 0,27-0,62	HR 0,30 0.23-0,41	HR 0.44 0.28-0,68	HR 0.31 0.2-0,47
HRD+BRCAwt	HR 0,50 0.31-0,83			HR 0.43 0.28-0,66
HRP	HR 0.68 0.49-0,94		HR 0.81 0.6-1,09	HR 0.92 0.72-1,17







SOLO1: After 5 years follow up the PFS benefit derived maintenance olaparib was sustained substantially beyond the end of treatment



October 5th, 2020

Investigator-assessed PFS

DCO: March 2020; Median follow-up: olaparib, 4.8 years, placebo, 5.0 years Cl=confidence interval; HR=hazard ratio; PFS=progression-free survival

ANGO IN GINECOLOGIA ONCOLOGICA


Maintenance olaparib in pts with newly diagnosed advanced EOC

Subgroup	Olaparib	Placebo	Hazard	Ratio for	Disease	Progressio	on or Death	
	no. of patients with disease progression				(95% (CI)		
	or death/to	tal no. (%)						
All patients	102/260 (39)	96/131 (73)		-•			0.30 (0.23-	-0.41
Clinical response after chemotherapy						i		
Complete response	73/213 (34)	73/107 (68)		_	-		0.35 (0.26-	-0.49
Partial response	29/47 (62)	23/24 (96)	-	•		1	0.19 (0.11-	0.34
ECOG performance status at baseline								
Normal activity	75/200 (38)	76/105 (72)				1	0.33 (0.24-	0.46
Restricted activity	27/60 (45)	20/25 (80)		-	•	.	0.38 (0.21-	-0.68
CA-125 level at baseline						i		
≤ULN	92/247 (37)	89/123 (72)		_)—	-	0.34 (0.25-	-0.46
>ULN	10/13 (77)	7/7 (100)				1	NC	
Germline BRCA mutation according to testing at M	yriad					1		
BRCA1	84/188 (45)	69/91 (76)		(<u>-</u>	•	1	0.40 (0.29-	-0.56
BRCA2	15/62 (24)	26/39 (67)	-	•	-	1	0.20 (0.10-	0.38
BRCA1 and BRCA2	0/3	0/0				i	NC	
None	3/7 (43)	1/1 (100)				1	NC	
Age at baseline						1		
<65 yr	85/225 (38)	82/112 (73)				1	0.33 (0.24-	0.45
≥65 yr	17/35 (49)	14/19 (74)				— i	0.45 (0.22-	-0.92
International FIGO stage at initial diagnosis						1		
Stage III	83/220 (38)	79/105 (75)		_	-		0.32 (0.24-	0.44
Stage IV	19/40 (48)	17/26 (65)				— !	0.49 (0.25-	-0.94
Presence of residual macroscopic disease after						i.		
debulking surgery performed before trial entry						1		
Yes	29/55 (53)	23/29 (79)		-	•	- 1	0.44 (0.25-	-0.77
No	70/200 (35)	69/98 (70)		_		1	0.33 (0.23-	-0.46
		0.0625	0.1250	0.2500	0.5000	1.0000	2.0000	
		-	ol	arib Bett			ebo Better	




Banerjee et al. 2021

PRIMA Trial Design






PRIMA Primary Endpoint, PFS Benefit in the HR-deficient Population






PRIMA Primary Endpoint, PFS Benefit in the Overall Population









- Niraparib provided similar clinical benefit in the HRd subgroups (BRCAmut and BRCAwt)
- Niraparib provide clinically significant benefit in the HR-proficient subgroup with a 32% risk reduction in progression or death

Cl, confidence interval; HR, homologous recombination; mut, mutation; PFS, progression-free survival wt, wild-type.



congress

Niraparib in pts with newly diagnosed advanced EOC

Subgroup	Niraparib	Placebo	Hazard Ratio for Disease I	Progression or Death (95% CI)
	no. of patients with disease progression or death/total no. (%)			
All patients	232/487 (47.6)	155/246 (63.0)		0.62 (0.50-0.76)
Age				
<65 yr	136/297 (45.8)	86/147 (58.5)		0.61 (0.47-0.81)
≥65 yr	96/190 (50.5)	69/99 (69.7)	• •	0.53 (0.38-0.74)
ECOG score				
0	146/337 (43.3)	107/174 (61.5)	_ _	0.60 (0.46-0.77)
1	86/150 (57.3)	48/72 (66.7)		0.69 (0.48-1.00)
Stage of disease at initial diagnosis				
III	143/318 (45.0)	103/158 (65.2)	_	0.54 (0.42-0.70)
IV	89/169 (52.7)	52/88 (59.1)		0.79 (0.55-1.12)
Neoadjuvant chemotherapy			1	
Yes	151/322 (46.9)	107/167 (64.1)		0.59 (0.46-0.76)
No	81/165 (49.1)	48/79 (60.8)	i	0.66 (0.46-0.94)
Best response to platinum therapy	,			
Complete response	146/337 (43.3)	100/172 (58.1)	i	0.60 (0.46-0.77)
Partial response	86/150 (57.3)	55/74 (74.3)		0.60 (0.43-0.85)
Geographic region			1	
North America	104/218 (47.7)	82/115 (71.3)		0.50 (0.37-0.68)
All other regions	128/269 (47.6)	73/131 (55.7)	i	0.72 (0.54-0.96)
Homologous-recombination status				
BRCA mutation	49/152 (32.2)	40/71 (56.3)		0.40 (0.27-0.62)
No BRCA mutation, homologous- recombination deficiency	32/95 (33.7)	33/55 (60.0)		0.50 (0.31-0.83)
Homologous-recombination proficiency	111/169 (65.7)	56/80 (70.0)		0.68 (0.49–0.94)
Not determined	40/71 (56.3)	26/40 (65.0)	•	0.85 (0.51–1.43)
		0.2	5 0.50 1.00	2.00
			 Niraparib Better Pl 	acebo Better



Ricerca Clinica e Traslazionale in Ginecologia Oncologica Gonzales-martin et al. 2019

Niraparib in pts with newly diagnosed advanced EOC

Different populations of SOLO1 and PRIMA trials (not only as for BRCA or HRD) More pts in SOLO 1 had stage III disease (83% versus 65%) and underwent PDS with no macroscopic RD (44% versus 0.4%)


> Risk of progression HR (95% CI) 0.44 (0.25-0.77)

Olaparib-treated pts with RD after surgery (SOLO1 trial)

Niraparib- treated pts with BRCA mutation0.40 (0.27-0.62)and RD after surgery (PRIMA trial)



PFS by surgical status – Primary debulking surgery




In patients who received PDS, 16 patients' residual disease status was unknown.

CI, confidence Interval; HR, hazard ratio; mPFS, median PFS; PDS, primary debuilking surgery; PFS, progression-free survival O'Cearbhall R, et al. presented at SGO 2021, 19–25 Mar (virtual).

PDS

PFS by surgical and VRD status – Primary debulking surgery with visible residual disease



CI, confidence interval; HR, hazard ratio; mPFS, median PFS; PDS, primary debulking surgery; PFS, progression-free survival; VRD, visible residual disease. O'Cearthail R, et al. presented at SGO 2021, 19–25 Mar (virtual).


FOR REACTIVE USE ONLY

62


gsk








PFS by surgical and VRD status – Interval debulking surgery with visible residual disease








Study design

Newly diagnosed FIGO stage III-IV high-grade serous/endometrioid ovarian, fallopian tube or primary peritoneal cancer*






*Patients with other epithelial non-mucinous ovarian cancer were eligible if they had a germline BRCA1 and/or BRCA2 mutation *Bevacizumab: 15 mg/kg, every 3 weeks for a total of 15 months, including when administered with chemotherapy; *By central labs; *According to timing of surgery and NED/CR/PR BICR, blinded independent central review; HRQoL, health-related quality of life; PFS2, time to second progression or death; RECIST, Response Evaluation Criteria in Solid Turnours; TFST, time to first subsequent therapy or death; TSST, time to second subsequent therapy or death






PFS by investigator assessment: ITT population







PFS by HRD status



The percentages of patients progression-free at 12 months and 24 months have been calculated based on Kaplan-Meier estimates. HRD positive is an HRD score ≥42. "This median is unstable due to a lack of events – less than 50% maturity




Maintenance olaparib + BEV in pts with newly diagnosed advanced HGSOC: Final analysis of second progressionfree survival (PFS2) in PAOLA-1/ENGOT-ov25 trial

	Olaparib + BEV vs PL + BEV				
	median PFS2 (months)	HR (95% CI)			
ITT	36.5 vs 32.6	0.78 (0.64 -0.95)			
BRCA mutations	NR vs 45	0.53			
HRD	50.3 vs 35	0.56			
HRD tumors without BRCA mutations	50.3 vs 30.1	0.60			

Gonzales-Martin et al. 2021



Olaparib + BEV improved PFS regardless of FIGO stage in HRD-positive pts




DCO 22 March 2019.

*HRD-positive defined as BRCAm and/or genomic instability score ≥42 in the Myriad myChoice® CDx


Cl=confidence interval; HR=hazard ratio; HRD=homologous recombination deficiency; PFS=progression-free survival

Pautier P, et al. Presented at ASCO Annual Meeting 2021. 4-8 Jun





Olaparib + BEV resulted in PFS2 benefit regardless of FIGO stage in HRD-positive pts



DCO 22 March 2019.

*HRD-positive defined as BRCAm and/or genomic instability score ≥42 in the Myriad myChoice® CDx


Cl=confidence interval; HR=hazard ratio; HRD=homologous recombination deficiency; PFS=progression-free survival; NR=not reached; PFS2=second progression-free survival

^{*}Unstable median due to lack of events

Pautier P, et al. Presented at ASCO Annual Meeting 2021. 4-8 Ju



3-year PFS2 rate was >90% in HRD-positive pts who had complete resection during upfront surgery



*HRD-positive defined as BRCAm and/or genomic instability score ≥42 in the Myriad myChoice® CDx

Cl=confidence interval; HR=hazard ratio; HRD=homologous recombination deficiency; NR=not reached; PFS2=second progression-free survival




Differences between PAOLA-1 and SOLO1

Study results not directly comparable without adjustment of the populations

only PTS with a BRCAm were included in SOLO-1, and a different comparator arm was used

PAOLA-1



*Patients with other epithelial non-mucinous ovarian cancer were eligible if they had a germline BRCA1 and/or BRCA2 mutation; ¹Bevacizumab: 15 mg/kg, every 3 weeks for a total of 15 months, including when administered with chemotherapy; ¹By central labs; ¹According to timing of surgery and NED/CR/PR

bid=twice daily; BRCAm=BRCA1 and/or BRCA2 mutation; CR=complete response; ECOG=Eastern Cooperative Oncology Group; FIGO=Federation of Gynecology and Obstetrics; HGEOC=high-grade endometrioid ovarian cancer; HGSOC=high-grade serous ovarian cancer; NED=no evidence of disease; PR=partial response; tBRCAm=tumour BRCA1 and/or BRCA2 mutation

195-2505; 3. Ray-Coquard I, et al. N Engl J Med. 2019;381:2416-2428

SOLO-1



Population-adjusted ITC methodology

Population-adjusted ITC can estimate the relative treatment effect when comparing studies which do not have common comparator arm


A **propensity score weighting technique** was used to minimise differences in observable characteristics between the trial populations

Weighted cox regression and Kaplan-Meier analyses were used to compare efficacy by investigatorassessed PFS (RECIST v1.1)

All analyses were performed in patients with complete baseline data. BRCAm=mutation in *BRCA12*; ITC=indirect treatment comparison; PFS=progression-free survival; RECIST=Response Evaluation Criteria in Solid Tumors




BEV monotherapy vs. placebo



Months since randomisation




Olaparib monotherapy vs BEV monotherapy



Months since randomisation




Olaparib + BEV vs Olaparib monotherapy




Months since randomisation





Study Design: VELIA/GOG-3005 (NCT02470585)













BARCELORA ENO

Median duration of follow-up was 28 months at the time of database lock.







PARPi in 1st line of advanced EOC: ongoing trials

- NCT04227522 Rucaparib Maintenance After Bevacizumab Maintenance Following CBDCA - Based First Line Chemotherapy in EOC (MAMOC)
- NCT04532645 A Pan-European Non-interventional, Retrospective Observational Cohort Study of pts With BRCA Mutated FIGO Stage III-IV Ovarian Cancer Treated With Olaparib Tablets in the First-line Maintenance
- NCT03462212A Randomized, Molecular Driven Phase II Trial of CBDCA+PTX+BEV vs CBDCA + PTX + BEV + rucaparib vs CDDCA + PTX + Rucaparib, Selected According to HRD Status, in pts With Advanced (Stage III B-C-IV) Ovarian, Primary Peritoneal and Fallopian Tube Cancer (MITO 25)



Immunotherapy trials in 1^{st-}line of EOC

NCT02718417 Randomized, Open-label, Multicenter, Phase 3 Study To Evaluate Efficacy And Safety of Avelumab in Combination with And/Or Following Chemotherapy in Pts with Previously untreated EOC (JAVELIN OVARIAN 100) NCT03038100 A Phase III, Multicenter, Randomized, Study of Atezolizumab vs Placebo Administered in Combination With PTX+ CBDCA + BEV in Pts With Newly-Diagnosed Stage III-IV EOC (IMagyn050)




Immunotherapy trials in 1st-line of EOC

NCT03740165	Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First-Line Treatment of BRCA Non-mutated Advanced EOC (KEYLYNK-001 / ENGOT-ov43 / GOG-3036
NCT03522246	A Multicenter, Randomized, Double-Blind, Placebo- Controlled Phase 3 Study in EOC Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based CT (ATHENA) (rucaparib + nivolumab, rucaparib+ placebo, oral placebo+ nivolumab, oral placebo + IV placebo)



Available 1st-line maintenance therapy options

	Niraparib	Olaparib	Olaparib + Bevacizumab	Bevacizumab
***** * * *	All comers	BRCAm	BRCAm or HRD	All comers





Algorithm for 1st line of advanced EOC

- ✓ All pts start treatment with the first cycle of q3w PTX 175 mg/m² + CBDCA AUC5 regimen.
- ✓ The results of BRCA testing on tissue samples collected at PDS or laparoscopy or CT/US- guided biopsies should be available before the second cycle
- ✓ BRCA mutated: PTX/CBDCA followed by olaparib maintenance in responsive cases according to SOLO1 trial [HR=0.33].
- ✓ BRCA wild-type: Clinical behavior depends on both the availability of HRD assay as well as by the presence or lack of risk factors for BEV- related AE



Algorithm for 1st line of advanced BRCA-wt EOC

Not available HRD assay

✓ No contraindications to BEV: BEV can be added concurrently PTX/CBDCA and sequentially as maintenance according to GOG 218
 ✓ Contraindications to BEV: PTX/CBDCA eventually followed by niraparib according to PRIMA (niraparib →absolute median PFS benefit of 5.6 months [HR=0.62] in ITT population)



Algorithm for 1st line of advanced BRCA-wt EOC

Positive HRD assay

No contraindications to BEV: BEV can be added concurrently to PTX/CBDCA and then sequentially and olaparib can be added as maintenance according to PAOLA-1(Olaparib + BEV-> median absolute PFS benefit of 11.5 mos [HR=0.43] vs PL+BEV in pts with HRD and BRCA-wt
 Contraindications to BEV: PTX/CBDCA followed by niraparib according to PRIMA (niraparib-> absolute median PFS benefit of 11.4 months [HR=0.50] vs PL in pts with HRD and BRCA-wt)



Algorithm for 1st line of advanced BRCA-wt EOC

Negative HRD assay

- ✓ No contraindications to BEV: BEV can be added concurrently to PTX/CBDCA and then sequentially as maintenance [according to GOG218]
 ✓ Contraindications to BEV: PTX/CBDCA eventually followed by niraparib according to PRIMA (Niraparib → absolute median PFS benefit of 2.7 months only [HR=0.68) vs PL in pts with HRP)
- \checkmark The role of immunotherapy in first line treatment is still investigational

